Bartlett & Co’s Jazz Pharmaceuticals JAZZ Stock Holding History

Bartlett & Co’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-15	Closed	-$2K	–	647
2021 Q3	$2K	Sell	15 -3	-17%	-$453	﹤0.01%	873
2021 Q2	$3K	Sell	18 -547	-97%	-$94.8K	﹤0.01%	804
2021 Q1	$93K	Hold	565	–	–	﹤0.01%	430
2020 Q4	$93K	Buy	565 +15	+3%	+$2.23K	﹤0.01%	424
2020 Q3	$78K	Hold	550	–	–	﹤0.01%	420
2020 Q2	$61K	Hold	550	–	–	﹤0.01%	458
2020 Q1	$55K	Buy	+550	New	+$71.1K	﹤0.01%	445
2019 Q3	$70K	Hold	550	–	–	﹤0.01%	453
2019 Q2	$78K	Hold	550	–	–	﹤0.01%	357
2019 Q1	$79K	Hold	550	–	–	﹤0.01%	346
2018 Q4	$68K	Hold	550	–	–	﹤0.01%	356
2018 Q3	$92K	Hold	550	–	–	﹤0.01%	332
2018 Q2	$95K	Hold	550	–	–	﹤0.01%	332
2018 Q1	$83K	Hold	550	–	–	﹤0.01%	354
2017 Q4	$74K	Hold	550	–	–	﹤0.01%	377
2017 Q3	$80K	Hold	550	–	–	﹤0.01%	359
2017 Q2	$86K	Hold	550	–	–	﹤0.01%	337
2017 Q1	$80K	Hold	550	–	–	﹤0.01%	347
2016 Q4	$60K	Hold	550	–	–	﹤0.01%	396
2016 Q3	$67K	Buy	+550	New	+$74.1K	﹤0.01%	378

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Bartlett & Co's JAZZ Position: Q4 2021 in Review

Bartlett & Co sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2021, closing a stake of 15 shares — an estimated $2K sold.

Bartlett & Co first reported a position in JAZZ in Q3 2016 and held it in 20 quarters. The position peaked at $95K in Q2 2018. 454 funds tracked by Wall St. Rank hold JAZZ as of Q4 2021.

Bartlett & Co reported no remaining Jazz Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
Bartlett & Co sold 15 Jazz Pharmaceuticals shares in Q4 2021, an estimated $2K.
Bartlett & Co first reported a position in Jazz Pharmaceuticals in Q3 2016 and held it in 20 quarters.
Bartlett & Co's Jazz Pharmaceuticals position peaked at $95K in Q2 2018.
454 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2021.

Based on Bartlett & Co's 13F filing for Q4 2021, filed 8 Mar 2022.